

## Summary of the status of biologic medications in Canada

Province	Medication	Disease Type	Status in September, 2012	Status as of August, 2013
British Columbia	Belimumab (Benlysta®)	Systemic lupus erythematosus	Under review	Declined
	Rituximab (Rituxan®)	Vasculitis	Under review	Listed-CBC
	Tocilizumab (Actemra®)	Juvenile idiopathic arthritis	Under review	Listed-CBC
Alberta	Belimumab (Benlysta®)	Systemic lupus erythematosus	Under review	Under review
	Certolizumab pegol (Cimzia®)	Rheumatoid arthritis	Under review	Under review
	Rituximab (Rituxan®)	Vasculitis	Under review	Listed-CBC
	Tocilizumab (Actemra®)	Rheumatoid arthritis	Listed-ORC	Listed-CBC
Juvenile idiopathic arthritis		Under review	Listed-CBC	
Saskatchewan	Belimumab (Benlysta®)	Systemic lupus erythematosus	Under review	Declined
	Certolizumab pegol (Cimzia®)	Rheumatoid arthritis	Under review	Under review
	Rituximab (Rituxan®)	Vasculitis	Under review	Listed-CBC
	Tocilizumab (Actemra®)	Juvenile idiopathic arthritis	Under review	Listed-CBC
Manitoba	Abatacept (Orencia®)	Juvenile idiopathic arthritis	Under review	Under review
	Belimumab (Benlysta®)	Systemic lupus erythematosus	Under review	Under review
	Certolizumab pegol (Cimzia®)	Rheumatoid arthritis	Under review	Under review
	Etanercept (Enbrel®)	Juvenile idiopathic arthritis	Unknown	Unknown
	Golimumab (Simponi®)	Rheumatoid arthritis	Under review	Listed-CBC
		Ankylosing spondylitis	Under review	Listed-CBC
		Psoriatic arthritis	Under review	Listed-CBC
	Rituximab (Rituxan®)	Vasculitis	Under review	Under review
Tocilizumab (Actemra®)	Juvenile idiopathic arthritis	Under review	Listed-CBC	
Ontario	Abatacept (Orencia®)	Rheumatoid arthritis	Under review	Listed-CBC

	Adalimumab (Humira®)	Juvenile idiopathic arthritis	Not applicable	Listed-CBC
	Belimumab (Benlysta®)	Systemic lupus erythematosus	Under review	Under review
	Denosumab (Prolia®)	Osteoporosis	Under review	Under review
Quebec	Belimumab (Benlysta®)	Systemic lupus erythematosus	Under review	Under review
	Certolizumab pegol (Cimzia®)	Rheumatoid arthritis	Under review	Under review
	Rituximab (Rituxan®)	Vasculitis	Under review	Under review
	Tocilizumab (Actemra®)	Juvenile idiopathic arthritis	Under review	Listed-CBC
New Brunswick	Belimumab (Benlysta®)	Systemic lupus erythematosus	Under review	Under review
	Certolizumab pegol (Cimzia®)	Rheumatoid arthritis	Declined	Declined
	Infliximab (Remicade®)	Psoriatic arthritis	Declined	Declined
	Rituximab (Rituxan®)	Vasculitis	Under review	Listed-CBC
	Tocilizumab (Actemra®)	Juvenile idiopathic arthritis	Under review	Listed-CBC
Nova Scotia	Belimumab (Benlysta®)	Systemic lupus erythematosus	Under review	Under review
	Certolizumab pegol (Cimzia®)	Rheumatoid arthritis	Under review	Under review
	Infliximab (Remicade®)	Ankylosing spondylitis	Under review	Listed-CBC
		Psoriatic arthritis	Declined	Declined
	Rituximab (Rituxan®)	Vasculitis	Under review	Listed-CBC
	Tocilizumab (Actemra®)	Juvenile idiopathic arthritis	Under review	Listed-CBC
Newfoundland and Labrador	Belimumab (Benlysta®)	Systemic lupus erythematosus	Under review	Under review
	Certolizumab pegol (Cimzia®)	Rheumatoid arthritis	Under review	Under review
	Infliximab (Remicade®)	Psoriatic arthritis	Declined	Declined
	Rituximab (Rituxan®)	Vasculitis	Under review	Under review
	Tocilizumab (Actemra®)	Juvenile idiopathic arthritis	Under review	Under review
Prince Edward Island	Belimumab (Benlysta®)	Systemic lupus erythematosus	Under review	Under review

	Certolizumab pegol (Cimzia®)	Rheumatoid arthritis	Under review	Listed-CBC
	Denosumab (Prolia®)	Osteoporosis	Under review	Under review
	Infliximab (Remicade®)	Psoriatic arthritis	Under review	Under review
	Rituximab (Rituxan®)	Vasculitis	Under review	Under review
NIHB*	Belimumab (Benlysta®)	Systemic lupus erythematosus	Under review	Under review
	Certolizumab pegol (Cimzia®)	Rheumatoid arthritis	Declined	Listed-CBC
	Infliximab (Remicade®)	Ankylosing spondylitis	Declined	Declined
		Psoriatic arthritis	Declined	Declined
	Rituximab (Rituxan®)	Vasculitis	Under review	Under review
	Tocilizumab (Actemra®)	Juvenile idiopathic arthritis	Under review	Under review
Yukon	Abatacept (Orencia®)	Juvenile idiopathic arthritis	Under review	Under review
	Adalimumab (Humira®)	Ankylosing spondylitis	Under review	Under review
	Belimumab (Benlysta®)	Systemic lupus erythematosus	Under review	Under review
	Certolizumab pegol (Cimzia®)	Rheumatoid arthritis	Under review	Under review
	Denosumab (Prolia®)	Osteoporosis	Under review	Under review
	Etanercept (Enbrel®)	Ankylosing spondylitis	Under review	Under review
		Juvenile idiopathic arthritis	Under review	Under review
		Psoriatic arthritis	Under review	Under review
	Golimumab (Simponi®)	Rheumatoid arthritis	Under review	Under review
		Ankylosing spondylitis	Under review	Under review
		Psoriatic arthritis	Under review	Under review
	Infliximab (Remicade®)	Ankylosing spondylitis	Under review	Under review
		Psoriatic arthritis	Under review	Under review
	Rituximab (Rituxan®)	Vasculitis	Under review	Under review
	Tocilizumab (Actemra®)	Rheumatoid arthritis	Under review	Under review

\*Note: People living in the Northwest Territories and Nunavut, who do not have private health insurance, have coverage for those medications listed on the federal Non-Insured Health Benefits (NIHB) formulary.

### **Definitions**

**Declined:** The formulary does not reimburse patients prescribed this medication.

**Listed-CBC:** Each province and territory has a process by which medications that are not normally included in the provincial, territorial or federal drug benefit lists are covered (or reimbursed). Approval of this medication is granted on a case-by-case basis.

**Listed-ORC:** The medication is listed, but the criteria are not supported by medical evidence. Arthritis Consumer Experts considers these overly restrictive criteria (ORC) unacceptable.

**Not Applicable:** No Notice of Compliance (or NOC) has been issued for this medication for this form of arthritis.

**Under Review:** This medication has been approved by Health Canada for this disease type and the province is considering whether patients should be reimbursed for it.

**Unknown:** There is no public information available.